In particular, ERα/PR/HER2 triple-negative breast cancer (TNBC), which accounts for 15–25% of breast tumors [1], often has poorest prognosis due to this particular cancer's insensitivity to traditional endocrine therapies and HER2 targeted therapies [2]. Here, ERBB2 is linked to breast neoplasm.